Annexon (ANNX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.28

Estimate

-$0.24

Surprise

-15.2%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Annexon (ANNX) reported a wider loss than forecast — diluted EPS of -$0.28 against the -$0.24 estimate (a 15.2% shortfall).

• Citizens Upgrades Annexon to Market Perform — benzinga, 2026-08-13
• Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate — benzinga, 2026-08-12
• Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial A — benzinga, 2026-08-12

TrendMatrix currently rates ANNX Sell at 5.4/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -15.2% surprise compares with a +3.0% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$5.11

Price target

$12.80

Stop

$4.72

Upside to target

+150.5%

Reward-to-risk

14.2:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$961.2M

P/E (fwd)

-4.7

52-week range

$2.03–$7.18

Off 52-week high

28.8%

RSI (14)

45

Volume vs avg

0.57×

Score today

5.4/10